Troxipide, a novel antiulcer compound, has inhibitory effects on human neutrophil migration and activation induced by various stimulants

Kusugami, Kazuo; Ina, Kenji; Hosokawa, Takehiko; Kobayashi, Fumiyoshi; Kusajima, H.; Momo, Kenji; Nishio, Yuji

doi:10.1016/s1590-8658(00)80023-7

Cited by 14 publications

(16 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, rebamipide was shown to inhibit the H. pylori-induced production of IL-8 by acting as an oxygen radical scavenger, thereby preventing the oxidant-mediated activation of NF-κB [106]. Troxipide was shown to inhibit the IL-8-induced migration of neutrophils and to reduce the generation of reactive superoxide intermediates [107]. Ecabet sodium, which is derived from pine resin, inhibits the ability of H. pylori to stimulate the production of IL-8 and reactive oxygen intermediates by neutrophils [108].…”

Section: Gastric Cancermentioning

confidence: 99%

The role of CXC chemokines in the transition of chronic inflammation to esophageal and gastric cancer

Verbeke

Geboes

Damme

et al. 2012

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

View full text Add to dashboard Cite

Chronic inflammation may increase the risk to develop cancer, for instance esophagitis or gastritis may lead to development of esophageal or gastric cancer, respectively. The key molecules attracting leukocytes to local inflammatory sites are chemokines. We here provide a systematic review on the impact of CXC chemokines (binding the receptors CXCR1, CXCR2, CXCR3 and CXCR4) on the transition of chronic inflammation in the upper gastrointestinal tract to neoplasia. CXCR2 ligands, including GRO-α,β,γ/CXCL1,2,3, ENA-78/CXCL5 and IL-8/CXCL8 chemoattract pro-tumoral neutrophils. In addition, angiogenic CXCR2 ligands stimulate the formation of new blood vessels, facilitating tumor progression. The CXCR4 ligand SDF-1/CXCL12 also promotes tumor development by stimulating angiogenesis and by favoring metastasis of CXCR4-positive tumor cells to distant organs producing SDF-1/CXCL12. Furthermore, these angiogenic chemokines also directly enhance tumor cell survival and proliferation. In contrast, the CXCR3 ligands Mig/CXCL9, IP-10/ CXCL10 and I-TAC/CXCL11 are angiostatic and attract anti-tumoral T lymphocytes and may therefore mediate tumor growth retardation and regression. Thus, chemokines exert diverging, sometimes dual roles in tumor biology as described for esophageal and gastric cancer. Therefore extensive research is needed to completely unravel the complex chemokine code in specific cancers. Possibly, chemokine-targeted cancer therapy will have to be adapted to the individual's chemokine profile.

show abstract

Section: Gastric Cancermentioning

confidence: 99%

The role of CXC chemokines in the transition of chronic inflammation to esophageal and gastric cancer

Verbeke

Geboes

Damme

et al. 2012

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

View full text Add to dashboard Cite

show abstract

“…Troxipide has shown to inhibit neutrophil mediated inflammation [11] and oxidative stress [11–15] in addition to improving the gastric mucus composition and output [9, 16]. Furthermore, it has been found to increase the secretion of cytoprotective prostaglandins [10].…”

Section: Introductionmentioning

confidence: 99%

Troxipide in the Management of Gastritis: A Randomized Comparative Trial in General Practice

Dewan¹,

Balasubramanian²

2010

Gastroenterology Research and Practice

View full text Add to dashboard Cite

Background. A trial of empirical acid-suppressive therapy is the usual practice for most patients with symptoms of gastritis in primary care. Aim. To assess the relative efficacy of Troxipide and Ranitidine in patients with endoscopic gastritis over a four-week period. Methods. In all, 142 patients were randomized to Troxipide (100 mg tid) or Ranitidine (150 mg bid) for a period of four weeks. The severity of the signs of endoscopic gastritis at baseline and week 4 using a four-point scale and the subjective symptom severity at baseline and week 2 & week 4 using a Visual analog scale (VAS) were documented. Results. Troxipide was found to be superior to Ranitidine for both, the complete resolution and improvement of endoscopic gastritis. Higher proportion of patients showed complete healing of erosions (88.14%), oozing (96.77%), and edema (93.88%) with Troxipide as compared to Ranitidine (P < .01). Patients receiving Troxipide also showed a greater improvement in the VAS scores for abdominal pain, bloating, and heartburn (P < .01). Both the drugs were found to be well tolerated. Conclusion. In patients with endoscopic gastritis, Troxipide, with its superior rate of improvement, resolution of signs, and subjective clinical symptoms, can be considered as an alternative to the commonly used antisecretory agents.

show abstract

“…Antiulcer effect of troxipide is due to increase in gastric mucosal blood flow, mucus secretion (Mine et al, 1991), glycoprotein excretion in the gastric mucosa and inhibition of inflammatory responses and mucosal injury mediated by neutrophils (Kusugami et al, 2000). It increases gastric mucosal prostaglandin (PG) levels as evidenced in animal studies.…”

Section: Introductionmentioning

confidence: 99%

“…Production of reactive oxygen radicals is believed to be one of pathogenic factors involved in neutrophil induced gastric mucosal injury (Kusugami et al, 2000). Troxipide can prevent the generation of oxygen free radicals, thereby protecting the gastric mucosa (Momo et al, 1994).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Bioequivalence Study of Troxipide Tablet Formulations

Dewan¹,

Navajit²

2010

JBB

View full text Add to dashboard Cite

Troxipide is a novel gastro protective agent with antiulcer, anti-inflammatory and mucus secreting properties. This bioequivalence study was carried out to determine the pharmacokinetic profile of troxipide in plasma in an open label, comparative, randomized, two way cross over design involving two treatments and two periods with one week washout period in 28 healthy male subjects.Blood samples were collected at intervals up to 28 hours, as per the approved protocol. Plasma concentrations of troxipide were analyzed by high performance liquid chromatography (HPLC) and noncompartmental method was used for pharmacokinetic analysis. .10 h). There were no statistically significant differences between C max , AUC (0-t) and AUC (0-∞) and their log transformed data (p>0.05) for the test and reference formulations. The 90% of confidence intervals (C.I.s) for the test/reference ratio of mean C max , AUC (0-t) , and AUC (0-∞) were within the acceptable range of 80.00 to 125.00. The mean (±S.D.) times to maximal plasma concentration (t max ) of troxipide were 3.04±0.93 vs. 3.07±1.39 h for the test and the reference formulations respectively. Both the formulations were well tolerated.In conclusion, the two formulations were bioequivalent and may be used interchangeably.

show abstract

Troxipide, a novel antiulcer compound, has inhibitory effects on human neutrophil migration and activation induced by various stimulants

Cited by 14 publications

References 25 publications

The role of CXC chemokines in the transition of chronic inflammation to esophageal and gastric cancer

The role of CXC chemokines in the transition of chronic inflammation to esophageal and gastric cancer

Troxipide in the Management of Gastritis: A Randomized Comparative Trial in General Practice

Bioequivalence Study of Troxipide Tablet Formulations

Contact Info

Product

Resources

About